Education
About Us
Working with TipRanks
Follow Us
Cynata Therapeutics Limited (AU:CYP)
ASX:CYP
Total Valuation
Cynata Therapeutics Limited has a market cap or net worth of $44.06M. The enterprise value is AU$33.73M.
Market Cap$44.06M
Enterprise ValueAU$33.73M
Share Statistics
Cynata Therapeutics Limited has 225,954,380 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding225,954,380
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cynata Therapeutics Limited’s return on equity (ROE) is -1.35 and return on invested capital (ROIC) is -98.61%.
Return on Equity (ROE)-1.35
Return on Assets (ROA)-1.16
Return on Invested Capital (ROIC)-98.61%
Return on Capital Employed (ROCE)-1.22
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.28
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cynata Therapeutics Limited is -5.44. Cynata Therapeutics Limited’s PEG ratio is 0.12.
PE Ratio-5.44
PS Ratio0.00
PB Ratio7.34
Price to Fair Value7.34
Price to FCF-5.32
Price to Operating Cash Flow-5.32
PEG Ratio0.12
Income Statement
In the last 12 months, Cynata Therapeutics Limited had revenue of 2.32M and earned -9.74M in profits. Earnings per share was -0.05.
Revenue2.32M
Gross Profit2.32M
Operating Income-8.81M
Pretax Income-12.06M
Net Income-9.74M
EBITDA-9.95M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -8.03M and capital expenditures -50.00K, giving a free cash flow of -8.08M billion.
Operating Cash Flow-8.03M
Free Cash Flow-8.08M
Free Cash Flow per Share-0.04
Dividends & Yields
Cynata Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.05
52-Week Price Change-17.02%
50-Day Moving Average0.21
200-Day Moving Average0.22
Relative Strength Index (RSI)48.98
Average Volume (3m)186.24K
Important Dates
Cynata Therapeutics Limited upcoming earnings date is Sep 1, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend Date―
Financial Position
Cynata Therapeutics Limited as a current ratio of 5.58, with Debt / Equity ratio of 0.00%
Current Ratio5.58
Quick Ratio5.58
Debt to Market Cap0.00
Net Debt to EBITDA0.62
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cynata Therapeutics Limited has paid -2.32M in taxes.
Income Tax-2.32M
Effective Tax Rate0.19
Enterprise Valuation
Cynata Therapeutics Limited EV to EBITDA ratio is -4.70, with an EV/FCF ratio of -4.70.
EV to Sales20.20
EV to EBITDA-4.70
EV to Free Cash Flow-4.70
EV to Operating Cash Flow-4.70
Balance Sheet
Cynata Therapeutics Limited has $10.51M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -$10.51M billion.
Cash & Marketable Securities$10.51M
Total DebtAU$0.00
Net Cash-$10.51M
Net Cash Per Share-$0.05
Tangible Book Value Per Share$0.03
Margins
Gross margin is 91.93%, with operating margin of -380.37%, and net profit margin of -420.82%.
Gross Margin91.93%
Operating Margin-380.37%
Pretax Margin-520.82%
Net Profit Margin-420.82%
EBITDA Margin-429.70%
EBIT Margin-441.79%
Analyst Forecast
The average price target for Cynata Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast44.29%